Home > Insider Trading > Filing (0000805928-25-000041)

Filing Details

Accession Number:: 0000805928-25-000041
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-03-19 17:24:10
Reporting Period:: 2025-03-16

Filing Date:: 2025-03-19
Accepted Time:: 2025-03-19 17:24:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
805928	Axogen Inc.	AXGN	Electromedical & Electrotherapeutic Apparatus (3845)	411301878

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1595972	Wayne Erick Devinney	13631 Progress Blvd., Suite 400 Alachua FL 32615	Chief Innovation Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-03-16	2,950	$0.00	203,361	No	4	M	Direct
Common Stock	Acquisiton	2025-03-16	6,362	$0.00	209,723	No	4	M	Direct
Common Stock	Acquisiton	2025-03-16	23,150	$0.00	232,873	No	4	M	Direct
Common Stock	Disposition	2025-03-19	15,111	$17.50	217,762	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2025-03-16	2,950	$0.00	2,950	$0.00
Common Stock	Restricted Stock Units	Disposition	2025-03-16	6,362	$0.00	6,362	$0.00
Common Stock	Restricted Stock Units	Disposition	2025-03-16	23,150	$0.00	23,150	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	M	Direct
6,363	No	4	M	Direct
23,150	No	4	M	Direct

Footnotes

This reflects the number of restricted stock units that became vested as of March 16, 2025.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on March 16, 2025. This sale does not represent a discretionary trade by the Reporting Person.
The reported price in Column 4 is a weighted average sale price. These shares were sold on March 19, 2025 in multiple transactions at $17.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.
All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.